TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05528939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndeavorRx
Description: EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control video game
Description: The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
Study: NCT06096207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic SenSight Directional DBS lead
Description: At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic SenSight Directional DBS lead
Description: At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
Study: NCT06143878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study: NCT06102382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.1)
Description: An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.1 µg/kg/min till 5 minutes after delivery of the fetus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine (0.075)
Description: An intravenous bolus dose of norepinephrine (5 µg) followed by infusion of 0.075 µg/kg/min till 5 minutes after delivery of the fetus.
Study: NCT06143878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deucravacitinib
Description: Deucravacitinib will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.
Study: NCT05242484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered as subcutaneous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as subcutaneous injection.
Study: NCT05644977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emraclidine
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT06278363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Nursing care
Description: The Sexual Nursing Care approach is a specialized intervention for stroke patients and partners, addressing sexual health needs. It includes personalized counseling sessions with trained nurses, assessing dysfunctions and medical history. Active partner involvement fosters intimacy and understanding. Both receive sexual education covering anatomy, physiology, and post-stroke changes. Recommendations for activities like Kegel exercises are provided. Structured outpatient sessions occur, lasting 45 minutes, facilitated by a nurse. Pre- and post-treatment assessments are conducted to identify contraindications. Emerging issues during treatment are promptly communicated for management. Sexual Nursing Care aims to holistically address post-stroke sexual health and relational needs, improving awareness and communication.~Coaching and Counselling can be provided also via telemedicine.
Study: NCT05644977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT06278363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nursing Care
Description: Group 2 patients receive standard nursing care without structured interventions for sexual dysfunctions. Management relies on clinical case and routine care procedures. No specific sexual sphere interventions are provided. Any emerging issues needing diagnostic investigation are reported to the specialist. Both groups are assessed quantitatively for counseling effects on sexual and relational aspects and qualitatively for psychorelational changes and mood impact on couple's quality of life.
Study: NCT04864340

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE marked medical device
Description: Tetanic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE marked medical device
Description: Tetanic stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algometer
Description: Pressure stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algometer
Description: Pressure stimulation

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Non-nociceptive procedure (fine touch)
Study: NCT05644977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study: NCT06211764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAR-200
Description: Participants will receive TAR-200 intravesically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin C
Description: Participants will receive MMC intravesically.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Participants will receive gemcitabine intravesically.
Study: NCT03979742

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months
Study: NCT05351229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: 5 mcg/kg intrathecal preservative free morphine sulfate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline, placebo
Study: NCT04842513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multipeptide plus XS15
Description: The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
Study: NCT06385080

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously.
Study: NCT06308575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Given by PO
Study: NCT06163274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intravaginal Ring A
Description: Placebo Intravaginal Ring A consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 40A (Shore A hardness scale). The ring holds two blank grey cassettes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intravaginal Ring A
Description: Placebo Intravaginal Ring A consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 40A (Shore A hardness scale). The ring holds two blank grey cassettes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intravaginal Ring B
Description: Placebo Intravaginal Ring B consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 50A (Shore A hardness scale). The ring holds two blank grey cassettes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo Intravaginal Ring B
Description: Placebo Intravaginal Ring B consists of a flexible lavender silicone scaffold, with an outer diameter of 55 mm and a durometer value of 50A (Shore A hardness scale). The ring holds two blank grey cassettes.
Study: NCT05660434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma Inhaler with Bergamot essential oil
Description: The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
Study: NCT04649385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered orally once or twice daily (QD or BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered orally once or twice daily (QD or BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered 200 mg intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered 200 mg intravenous (IV) infusion
Study: NCT04585893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
Study: NCT06249347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROMISED
Description: CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Roof linear ablation: linear ablation in the left atria roof; Anterior septal linear ablation: linear ablation in the anterior septal linear which coursed from the middle of the right superior and inferior pulmonary veins or the middle of the right superior pulmonary vein to the mitral valve annulus; Mitral isthmus linear ablation: linear ablation in the mitral isthmus; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI and LAAC
Description: CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation catheter
Description: Device： Radiofrequency ablation catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation catheter
Description: Device： Radiofrequency ablation catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left atrial appendage occlusion device
Description: Device： left atrial appendage occlusion device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left atrial appendage occlusion device
Description: Device： left atrial appendage occlusion device
Study: NCT05529875

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: intravenous propofol using target-controlled infusion (TCI) devices.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
Study: NCT06407557

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Use of prompts to enable activity in older adults.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Use of prompts to enable activity in older adults.
Study: NCT04488354

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CLBR001 and SWI019
Description: No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
Study: NCT05558982

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL701
Description: BXCL701 0.3 mg, orally, twice a day on days 1-14 every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenous (IV) on day 1 every 21 days.
Study: NCT05771896

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darolutamide
Description: Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (\>56 days between cycles). Any participant requiring dose interruption \>28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (\>56 days between cycles). Any participant requiring dose interruption \>28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption \>28 consecutive days (\>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice.
Study: NCT06541028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid-Start ART (RS-ART)
Description: ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid-Start ART (RS-ART)
Description: ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART.
Study: NCT06094621

Intervention type: OTHER
Intervention: Survey
Description: For the patients who underwent a pre-operative virtual visit, data will be collected through semi-structured interviews conducted by trained research personnel. The interviews will be conducted in a one-on-one format, either in-person or via telephone, according to the participant's preference.
Study: NCT06590792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exhaustive exercise training session
Description: Cardiovascular exercise test will be performed by the participants. This test is sustained until the participants feel exhausted.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exhaustive exercise training session
Description: Cardiovascular exercise test will be performed by the participants. This test is sustained until the participants feel exhausted.
Study: NCT05519683

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEA
Description: The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEA
Description: The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEA
Description: The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
Study: NCT04699916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG based protocol for deep sedation
Description: Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
Study: NCT06656754

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Reaching
Description: The intervention of Isometric Reaching is the process of restricting the participant's hand movement in place, while using the forces they apply to the robot handle to drive a reaching arm simulation